Expansions - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

A roundup of manufacturing and service expansions.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 8

Laupheim, Germany (July 24)Rentschler Biotechnologie commissioned two new GMP manufacturing suites for producing therapeutic proteins and monoclonal antibodies. The new fermenter lines with 500 L of working volume are sized so different cell-culture processes can be run (batch, fed-batch, or perfusion). The company also is building two new 2500-L multiprocess fermentation suites, the first of which is slated for commissioning in mid-2008. Both can run perfusion processes. The expansion includes a new laboratory building, a central energy station, a logistics space, and additional facilities for sterile filling of syringes and injection vials.

Frankfurt (July 17)Evotec AG expanded its sterile-pharmaceutical manufacturing facility in Glasgow, United Kingdom. The company doubled its capacity for the aseptic GMP manufacture of clinical trial material.

In another development, Evotec AG and Research Support International Limited (RSIL) formed a joint venture in India, Evotec-RSIL Ltd, to design, synthesize, and manage compound libraries as a service. The joint venture will be located in Thane, India.

Research Triangle Park, NC (July 5)—Quintiles Transnational Corp. plans to expand and consolidate its Global Central Laboratories in Smyrna, Georgia, and its Clinical Development Services office in Atlanta, Georgia, within a single structure in nearby Marietta, Georgia. The 201,366-ft2, three-story structure in Marietta will more than double the combined space now occupied by Global Central Laboratories in Smyrna and CDS in Atlanta and allow the addition of about 400 jobs through 2011. Renovation of the structure is expected to begin in the third quarter of 2007.

Neuilly-sur-Seine, France (July 5)—Servier, an independent French drug company, opened a new manufacturing center in Sophyno, Russia, to produce brand-name drugs for the local market. The facility, the result of a EUR 40-million ($55-million) investment, is expected to produce 60 million packs and employ more than 180 people.

Surrey, UK (June 27)NextPharma Technologies announced a $41-million fundraising round, of which $22 million will be invested in expanding the company's injectable-cytotoxics manufacturing site in Braine L'Alleud, Belgium. This investment will more than double the facility's capacity, and the facility will be on line in 2009. NextPharma also acquired Bioserv Corp. (San Diego, CA), a contract manufacturing company.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here